1. Aquaporin-2 in Patients with Congestive Heart Failure (HF) {#sec1-ijms-17-00105}
=============================================================

The aquaporin family has various activities in the human body, such as mediating water transport, and cell adhesion, migration, proliferation, and differentiation \[[@B1-ijms-17-00105]\]. Of the aquaporin family members, aquaporin-2 has been characterized as an arginine vasopressin (AVP)-regulated water channel protein translocating between the apical plasma membrane and subapical vesicles in the principal cells of the collecting duct \[[@B2-ijms-17-00105]\].

The mechanisms of aquaporin-2-mediated water retention have been studied for the past 20 years \[[@B3-ijms-17-00105]\]. Secreted AVP binds to the AVP type-2 (V~2~) receptor located at the basolateral membrane of principal cells ([Figure 1](#ijms-17-00105-f001){ref-type="fig"}). Activation of the V~2~ receptor triggers the trafficking of aquaporin-2 from intracellular storage vesicles to the apical membrane by cAMP-dependent phosphorylation of aquaporin-2 \[[@B4-ijms-17-00105],[@B5-ijms-17-00105]\]. Translocation of aquaporin-2 to the apical membrane increases water permeability, thereby increasing urine osmolality (U-OSM) \[[@B6-ijms-17-00105]\].

Approximately 3% of aquaporin-2, in particular phosphorylated and translocated aquaporin-2, in the kidney tissue is excreted in urine \[[@B7-ijms-17-00105]\]. Therefore, urine aquaporin-2 is considered a marker of collecting duct responsiveness to AVP \[[@B8-ijms-17-00105]\].

Several techniques have been developed to quantify urine aquaporin-2, such as radioimmunoassay, Western blotting, and sandwich enzyme-linked immunosorbent assay \[[@B7-ijms-17-00105],[@B9-ijms-17-00105],[@B10-ijms-17-00105]\], and urine aquaporin-2 has been quantified in various clinical conditions including pregnancy \[[@B11-ijms-17-00105]\], liver cirrhosis \[[@B12-ijms-17-00105]\], syndrome of inappropriate secretion of antidiuretic hormone \[[@B5-ijms-17-00105]\], diabetes insipidus \[[@B4-ijms-17-00105]\], and HF \[[@B13-ijms-17-00105],[@B14-ijms-17-00105]\].
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In patients with congestive HF, AVP is inappropriately secreted through the activation of a non-osmotic pathway owing to reduced effective circulating volume, despite peripheral water retention \[[@B15-ijms-17-00105],[@B16-ijms-17-00105],[@B17-ijms-17-00105],[@B18-ijms-17-00105]\]. Secreted AVP stimulates the expression and translocation of aquaporin-2 at the apical membrane of the collecting duct \[[@B4-ijms-17-00105],[@B5-ijms-17-00105]\], thereby facilitating water retention and successive hypervolemic hyponatremia ([Figure 1](#ijms-17-00105-f001){ref-type="fig"}) \[[@B15-ijms-17-00105]\]. Therefore, urine aquaporin-2 level increases in patients with HF owing to inappropriately elevated serum AVP level. Plasma level of AVP increases in association with HF progression, accompanied by activation of the renin-angiotensin-aldosterone system and sympathetic nerve system, which facilitate water retention \[[@B15-ijms-17-00105],[@B16-ijms-17-00105],[@B17-ijms-17-00105],[@B19-ijms-17-00105]\]. Many studies have demonstrated that hyponatremia is a predictor of morbidity and mortality in patients with HF \[[@B20-ijms-17-00105],[@B21-ijms-17-00105],[@B22-ijms-17-00105],[@B23-ijms-17-00105]\].

2. Tolvaptan and Its Responsiveness {#sec2-ijms-17-00105}
===================================

Tolvaptan, the only commercially available vasopressin V~2~ receptor antagonist, thus far, has been recently developed as a promising agent to treat patients with congestive HF refractory to conventional diuretics \[[@B24-ijms-17-00105]\]. It has a unique therapeutic target: it blocks AVP-aquaporin-2 pathway, and increases the excretion of electrolyte-free water in urine ([Figure 1](#ijms-17-00105-f001){ref-type="fig"}). Many studies have demonstrated the short-term efficacy and safety of tolvaptan; it also ameliorates symptomatic congestion, normalizes hyponatremia to maintain hemodynamics and the sparing renal function, and terminates the vicious cycle of HF described above \[[@B25-ijms-17-00105],[@B26-ijms-17-00105],[@B27-ijms-17-00105],[@B28-ijms-17-00105],[@B29-ijms-17-00105],[@B30-ijms-17-00105],[@B31-ijms-17-00105],[@B32-ijms-17-00105],[@B33-ijms-17-00105],[@B34-ijms-17-00105],[@B35-ijms-17-00105]\]. However, these benefits may not be expected in non-responders, whose urine volume does not increase despite the administration of tolvaptan \[[@B36-ijms-17-00105]\]. Tolvaptan could not normalize serum sodium concentration, ameliorate symptomatic congestion, and improve renal function in non-responders. Moreover, indeterminate administration of tolvaptan to non-responders may result in a loss of the optimal timing of intensive treatment \[[@B37-ijms-17-00105]\].

Tolvaptan was not found to be superior to placebo in terms of long-term survival rate in the Efficacy of Vasopressin Antagonist in HF Outcome Study with Tolvaptan (EVEREST) trial \[[@B38-ijms-17-00105]\]. Considering that tolvaptan demonstrated improved survival rate over the placebo in patients with hyponatremia in this subanalysis \[[@B39-ijms-17-00105]\], it may improve long-term prognosis only in a specific population. Therefore, it is necessary to identify the optimal population, *i.e.*, responders \[[@B40-ijms-17-00105],[@B41-ijms-17-00105]\].

3. Tolvaptan and Aquaporin-2 {#sec3-ijms-17-00105}
============================

Several studies recently demonstrated that unresponsiveness to tolvaptan is associated with decreased renal function \[[@B42-ijms-17-00105],[@B43-ijms-17-00105],[@B44-ijms-17-00105]\]. Older patients with chronic kidney disease have a trend of physiological insipidus mellitus, and have reduced urine concentrating ability. Tolvaptan may not be able to inhibit the already-extinct AVP-aquaporin-2 system in the collecting duct, and the residual function of the collecting duct is essential for response to tolvaptan \[[@B40-ijms-17-00105],[@B45-ijms-17-00105]\]. Therefore, urine aquaporin-2 has been evaluated as a predictive "marker" of responsiveness to tolvaptan \[[@B46-ijms-17-00105]\].

We recently demonstrated that higher urine aquaporin-2 level at baseline relative to plasma AVP was a novel predictor of responsiveness to tolvaptan \[[@B37-ijms-17-00105]\], because urine aquaporin-2 level increases in association with AVP stimulation under the well-preserved function of the collecting duct. Higher level of urine aquaporin-2 is associated with elevated U-OSM in the responders \[[@B37-ijms-17-00105]\]. Thus, U-OSM could be an alternative to urine aquaporin-2 for the prediction of responses to tolvaptan \[[@B40-ijms-17-00105]\].

In contrast, urine aquaporin-2 levels in non-responders were not detectable, regardless of serum AVP level \[[@B37-ijms-17-00105]\]. In general, expression level of aquaporin-2 decreases in patients with chronic kidney disease \[[@B47-ijms-17-00105]\]. Sato *et al.* showed that aquaporin-2 is not expressed in the renal tissue of non-responders with diabetes nephropathy \[[@B48-ijms-17-00105]\]. However, not all patients with chronic kidney disease have reduced urine excretion of aquaporin-2. Some patients have preserved function of the collecting duct despite decreased glomerular filtration ratio, and such patients are classified as responders to tolvaptan \[[@B37-ijms-17-00105]\]. However, several studies reported that even patients with advanced chronic kidney disease responded to tolvaptan \[[@B43-ijms-17-00105],[@B44-ijms-17-00105],[@B45-ijms-17-00105],[@B49-ijms-17-00105],[@B50-ijms-17-00105]\]. Therefore, urine aquaporin-2 could be a novel predictor to estimate the responders to tolvaptan especially among those with chronic kidney disease.

Long-term improvements in survival and re-admission-free survival rate were observed in the responders receiving tolvaptan, who were defined by urine aquaporin-2, although the study was retrospective ([Figure 2](#ijms-17-00105-f002){ref-type="fig"}A,B) \[[@B37-ijms-17-00105]\]. In this study, potential response was defined as baseline urine aquaporin-2/serum AVP level \>1.4 × 10^3^ L/gCre, and those receiving tolvaptan were compared with propensity score-matched control group. In contrast, non-responders, whose urine aquaporin-2/erum AVP level \<1.4 × 10^3^ L/gCre, could neither achieve improvement in survival nor in re-admission-free survival rate despite tolvaptan administration, compared with propensity score-matched non-responders without tolvaptan ([Figure 2](#ijms-17-00105-f002){ref-type="fig"}A,B). Tolvaptan ameliorated symptomatic congestion, normalized hyponatremia, improved renal function, and reduced the dose of diuretics in the aquaporin-defined responders. These effects may improve patients' prognosis during long-term tolvaptan treatment. Prospective randomized trials are warranted to evaluate long-term improvement in the prognosis of the aquaporin-defined responders receiving tolvaptan.

![Kaplan-Meier curves showing survival and readmission-free survival rate stratified by the administration of tolvaptan in responders (**A**,**B**) and non-responders (**C**,**D**). R, responder; NR, non-responder; TLV, tolvaptan, AQP, aquaporin.](ijms-17-00105-g002){#ijms-17-00105-f002}

Measurement of urine aquaporin-2 is also useful in confirming the response to tolvaptan in a timely fashion. Martin *et al.* showed that urine aquaporin-2 level decreased accompanied by an increase in urine volume from 2 h after the administration of tolvaptan \[[@B14-ijms-17-00105]\]. Udelson *et al.* demonstrated a decrease in urine osmolality at 4 h after tolvaptan administration, which indicates decreased aquaporin-2 activity \[[@B31-ijms-17-00105]\]. The decreased level of urine aquaporin-2 is restored the next morning, but does not reach the baseline level, which may indicate prolonged blockade of V~2~ receptor by tolvaptan for \>24 h \[[@B51-ijms-17-00105]\]. In contrast, urine aquaporin-2 remained undetectable during tolvaptan treatment in the non-responders \[[@B51-ijms-17-00105]\]. Persistent undetectable level of urine aquaporin-2 regardless of tolvaptan administration indicates lack of response to tolvaptan.

4. Conclusions {#sec4-ijms-17-00105}
==============

In conclusion, urine aquaporin-2 is a novel predictor of responsiveness to tolvaptan, and the responders achieved amelioration of symptomatic congestion, normalization of hyponatremia, and improvement in renal function during tolvaptan treatment. Long-term prognosis in the aquaporin-defined responders during tolvaptan treatment should be confirmed in a prospective randomized trial in the future.
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